CNSI Cambridge Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (493)	1/24/1999 6:50:00 PM
From: Miljenko Zuanic	Read Replies (1) of 675

Mike: I had in mind 97 and Cerestat failure (not today CNSI position), when I had significant position on CNSI and consequently large losses. It was not disastrous, but I wish that I had listen others advice and did better job in regards the stroke therapy. I underestimated difficulty, problems, concept, modality, pharmacology, ...in stroke therapy, so I didn't combine this with other similar drug failure and known data on Cerestat. I was to optimistic and caught by surprise. Anyway, I learned the lesson. So, in comparison with today SUGN drugs in PIII trials and any prediction of the trials outcome, I had in mind that cancer therapy is more strait forward and easy (I hope) to evaluate new therapies and drugs in clinical trials. Hope this help and clear misunderstanding. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next